AstraZeneca News

ZS consultants began to measure the behavior of primary care physicians and specialists in 2008 when Chressanthis was at AstraZeneca Pharmaceuticals LP. They drew from ZS' annual AccessMonitor™ report, which since 2006 has tracked how frequently 300,000 physicians

some risk and fund some programmes is natural for us”. Read at Pharma Times [Free Reg Req'd] Read at Financial Times • Pharma Times [Free Reg Req'd] • Financial Times • AstraZeneca PLC • Biotech/Pharma - Alliances • Biotech/Pharma - Alliances (World)

two companies joined a growing list of UK businesses – including insurer Aviva, drugs group AstraZeneca and oil company Cairn Energy – where shareholders have expressed anger over what they regard as excessive boardroom pay. Over 17pc of investors failed to

up 5.99%. It rallied 27% since yesterday, but before that it had been tanked 20% since May 8th. Post your opinion here AstraZeneca Pharma gained as much as 8% on Friday to touch an intraday high of Rs 1,998 amid heavy volumes. At 11:46 hours IST, the share

Lilly & Co. (LLY) and AstraZeneca Plc (AZN) won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)’s Plavix after the drug lost U.S. patent protection yesterday. Lilly’s Effient and AstraZeneca’s

and GlaxoSmithKline: A chorus of mis-approval One of the more striking aspects about the potential billion-dollar acquisitions recently announced by UK drugs giants AstraZeneca and GlaxoSmithKline, which we discuss in more detail in A bargain missed, was the

2012 at McCormick Place in Chicago, Illinois. Array invented selumetinib and MEK162 and subsequently licensed them to AstraZeneca and Novartis, respectively. Three oral presentations at ASCO: Selumetinib Title: Phase II double-blind, randomized study of selumetinib

Lilly & Co. (LLY) and AstraZeneca Plc (AZN) won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)’s Plavix after the drug loses U.S. patent protection today. Lilly’s Effient and AstraZeneca’s Brilinta

high of Rs 2,649 touched on April 12, 2012, after gaining more than 100% within six months on speculation of delisting its shares from the Indian bourses. AstraZeneca Pharmaceuticals AB Sweden held 90% of AstraZeneca Pharma India as at March 31 2012.

most high profile bosses in the last couple of months, among them David Brennan, the chief executive of drugs giant AstraZeneca (LON:AZN). After six years in the role, Brennan is leaving under a cloud of concern about the drug giant’s ability to replenish